188 related articles for article (PubMed ID: 31012422)
1. Regulating Nanomedicine at the Food and Drug Administration.
Paradise J
AMA J Ethics; 2019 Apr; 21(4):E347-355. PubMed ID: 31012422
[TBL] [Abstract][Full Text] [Related]
2. Reflections on FDA Draft Guidance for Products Containing Nanomaterials: Is the Abbreviated New Drug Application (ANDA) a Suitable Pathway for Nanomedicines?
Emily M; Ioanna N; Scott B; Beat F
AAPS J; 2018 Aug; 20(5):92. PubMed ID: 30128758
[TBL] [Abstract][Full Text] [Related]
3. Regulating nanomedicine - can the FDA handle it?
Bawa R
Curr Drug Deliv; 2011 May; 8(3):227-34. PubMed ID: 21291376
[TBL] [Abstract][Full Text] [Related]
4. Equivalence of complex drug products: advances in and challenges for current regulatory frameworks.
Hussaarts L; Mühlebach S; Shah VP; McNeil S; Borchard G; Flühmann B; Weinstein V; Neervannan S; Griffiths E; Jiang W; Wolff-Holz E; Crommelin DJA; de Vlieger JSB
Ann N Y Acad Sci; 2017 Nov; 1407(1):39-49. PubMed ID: 28445611
[TBL] [Abstract][Full Text] [Related]
5. Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars.
Mühlebach S; Borchard G; Yildiz S
Nanomedicine (Lond); 2015 Mar; 10(4):659-74. PubMed ID: 25723097
[TBL] [Abstract][Full Text] [Related]
6. Nanotechnology and therapeutic delivery: a drug regulation perspective.
Sadrieh N; Tyner KM
Ther Deliv; 2010 Jul; 1(1):83-9. PubMed ID: 22816122
[TBL] [Abstract][Full Text] [Related]
7. Draft guidance for industry on developing medical imaging drugs and biologics; availability--FDA. Availability of guidance.
Fed Regist; 1998 Oct; 63(198):55067-9. PubMed ID: 10185833
[TBL] [Abstract][Full Text] [Related]
8. Nanotherapeutics--product development along the "nanomaterial" discussion.
Wacker MG
J Pharm Sci; 2014 Mar; 103(3):777-84. PubMed ID: 24481705
[TBL] [Abstract][Full Text] [Related]
9. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
10. FDA final guidance on software validation.
Donawa M
Med Device Technol; 2002 Apr; 13(3):20-4. PubMed ID: 12030100
[TBL] [Abstract][Full Text] [Related]
11. FDA use of international standards in the premarket review process.
Rechen E; Barth DJ; Marlowe D; Kroger L
Biomed Instrum Technol; 1998; 32(5):518-26. PubMed ID: 9800008
[TBL] [Abstract][Full Text] [Related]
12. Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties.
Nijhara R; Balakrishnan K
Nanomedicine; 2006 Jun; 2(2):127-36. PubMed ID: 17292125
[TBL] [Abstract][Full Text] [Related]
13. The road to market implantable drug delivery systems: a review on US FDA's regulatory framework and quality control requirements.
Al-Jawadi S; Capasso P; Sharma M
Pharm Dev Technol; 2018 Dec; 23(10):953-963. PubMed ID: 30084277
[TBL] [Abstract][Full Text] [Related]
14. Evaluating oversight of human drugs and medical devices: a case study of the FDA and implications for nanobiotechnology.
Paradise J; Tisdale AW; Hall RF; Kokkoli E
J Law Med Ethics; 2009; 37(4):598-624. PubMed ID: 20122103
[TBL] [Abstract][Full Text] [Related]
15. Data Integrity: History, Issues, and Remediation of Issues.
Rattan AK
PDA J Pharm Sci Technol; 2018; 72(2):105-116. PubMed ID: 29158286
[TBL] [Abstract][Full Text] [Related]
16. The need for robust characterization of nanomaterials for nanomedicine applications.
Mahmoudi M
Nat Commun; 2021 Sep; 12(1):5246. PubMed ID: 34475383
[TBL] [Abstract][Full Text] [Related]
17. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review.
Tyner K; Sadrieh N
Methods Mol Biol; 2011; 697():17-31. PubMed ID: 21116951
[TBL] [Abstract][Full Text] [Related]
18. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring. Food and Drug Administration, HHS. Final rule.
Fed Regist; 1999 May; 64(94):26657-70. PubMed ID: 10558516
[TBL] [Abstract][Full Text] [Related]
19. Updated Regulatory Considerations for Nanomedicines.
Subin TS; Vijayan V; Kumar KJR
Pharm Nanotechnol; 2017; 5(3):180-191. PubMed ID: 28641516
[TBL] [Abstract][Full Text] [Related]
20. Revisions to the general safety requirements for biological products--FD. Direct final rule.
Fed Regist; 1998 Apr; 63(75):19399-403. PubMed ID: 10178869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
